Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 4:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 154 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: IV insulin Clear all
Completed Not applicable Interventional Results available

Trial Between a Computer-Guided Insulin Infusion Protocol Versus a Standard Insulin Infusion Algorithm in Medical ICU

NCT00394524
View directory record Official record
Conditions
Diabetes or With New Hyperglycemia
Interventions
Glucommander, Standard insulin infusion algorithm
Device · Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Atlanta, Georgia • Memphis, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 29, 2018 · Synced Sep 9, 2026, 4:46 AM EDT
Completed No phase listed Observational Results available

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

NCT05214573
View directory record Official record
Conditions
Type 2 Diabetes, Cardiac Disease
Interventions
Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
386,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 9, 2026, 4:46 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

NCT07167693
View directory record Official record
Conditions
Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions
Arginine hydrochloride, Sodium Chloride 0.9%
Drug
Lead sponsor
David K Carroll
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 9, 2026, 4:46 AM EDT
Terminated Not applicable Interventional Results available

Two Bag System for Diabetic Ketoacidosis

NCT03660189
View directory record Official record
Conditions
Diabetic Ketoacidosis
Interventions
Two bag system
Other
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Sep 9, 2026, 4:46 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants

NCT03253263
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Chronic Lung Disease of Prematurity, Intraventricular Hemorrhage, Retinopathy of Prematurity (ROP)
Interventions
OHB-607
Drug
Lead sponsor
OHB Neonatology Ltd.
Industry
Eligibility
0 Hours to 24 Hours
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
24
States / cities
Little Rock, Arkansas • California City, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Not applicable Interventional Results available

Glutathione Metabolism in Adolescents With Type 1 Diabetes - Study A

NCT00858897
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Cysteine isotope infusion at normoglycemia vs hyperglycemia, Regular Insulin
Other · Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
14 Years to 18 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 9, 2023 · Synced Sep 9, 2026, 4:46 AM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Pulsatile Intravenous (IV) Insulin on Wound Healing in Diabetics

NCT00967837
View directory record Official record
Conditions
Wound Healing, Diabetes
Interventions
Pulsatile Intravenous Insulin Therapy
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Use of an Insulin Infusion Conversion Equation (IICE) to Control Blood Glucose in Hospitalized Patients

NCT00645827
View directory record Official record
Conditions
Glucose, Blood
Interventions
IICE Dosing, Healthcare Provider dosing
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2014 · Synced Sep 9, 2026, 4:46 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.

NCT07546942
View directory record Official record
Conditions
Autism Spectrum Disorder, Autism, Autism Spectral Disorder
Interventions
Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol, Trial combines use of cSVF and MSCs (cryopres) with diet modification and FMT (fecal material Transplant in adult ASD patients, FMT (Fecal Material Tranplantation), Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation
Procedure · Dietary Supplement · Behavioral + 1 more
Lead sponsor
Black Tie Medical, Inc.
Industry
Eligibility
10 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Hamilton, Montana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Phase 1 Interventional

Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment

NCT00880282
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
cixutumumab, temsirolimus, pharmacological study, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 21 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
21
States / cities
Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of BFKB8488A in Otherwise Healthy Overweight and Obese Participants With Likely Insulin Resistance

NCT02593331
View directory record Official record
Conditions
Insulin Resistance
Interventions
BFKB8488A, Placebo
Drug · Other
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer

NCT01322802
View directory record Official record
Conditions
Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor
Interventions
pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine, laboratory biomarker analysis
Biological · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Autonomic Nervous System and the Metabolic Syndrome

NCT00580957
View directory record Official record
Conditions
Obesity
Interventions
Blocked, Intact
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 4, 2016 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Phase 1 Interventional

Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R

NCT02045368
View directory record Official record
Conditions
Breast Cancer, Brain Cancer, Gastrointestinal Cancers, Genitourinary Cancers, Gynecologic Cancers, Head and Neck Cancers, Melanoma, Thoracic Cancers
Interventions
IGF-Methotrexate conjugate
Drug
Lead sponsor
IGF Oncology, LLC
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intrapartum Glycemic Control With Insulin Infusion Versus Rotating Fluids

NCT03912363
View directory record Official record
Conditions
Type II Diabetes Mellitus, Gestational Diabetes Mellitus
Interventions
Rotating fluids protocol, Insulin infusion protocol
Other
Lead sponsor
Geisinger Clinic
Other
Eligibility
14 Years to 50 Years · Female only
Enrollment
114 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
Danville, Pennsylvania • Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2025 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma

NCT00813605
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
FOLFIRI, AMG 655, Placebo, AMG 479
Other · Biological
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
28
States / cities
Beverly Hills, California • Los Angeles, California • Santa Maria, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Phase 2 Interventional

LEA29Y (Belatacept) Emory Edmonton Protocol

NCT00468403
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 9, 2026, 4:46 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Evaluation of Kisspeptin Glucose-Stimulated Insulin Secretion With Physiologic Mixed Meal Tolerance

NCT04532801
View directory record Official record
Conditions
Insulin, Glucose, Healthy Volunteers, Women, Pregnancy
Interventions
Kisspeptin-10, mixed meal tolerance test
Drug · Other
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Sep 9, 2026, 4:46 AM EDT
Terminated Phase 2Phase 3 Interventional

Effects of Pulsatile Insulin Delivery on Diabetic Neuropathy in Patients With Types 1 and 2 Diabetes Mellitus

NCT00228891
View directory record Official record
Conditions
Diabetes Mellitus, With Complications
Interventions
Effect of Pulsatile IV Insulin on diabetic neuropathy
Procedure
Lead sponsor
Florida Atlantic University
Other
Eligibility
20 Years to 90 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Sep 9, 2026, 4:46 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Study of Fat Tissue's Ability to Take up Sugar in the Obese Population

NCT02994459
View directory record Official record
Conditions
Glucose Metabolism Disorders
Interventions
Weight Loss
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 64 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 9, 2026, 4:46 AM EDT
Active, not recruiting Phase 2 Interventional

Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer

NCT05090358
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Stage IV, Metastatic Breast Cancer
Interventions
Ketogenic Diet, Low Carbohydrate Diet, Alpelisib, Fulvestrant, Canagliflozin
Dietary Supplement · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
9
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Phase 3 Interventional Results available

Intensive Insulin Therapy in Patients Undergoing Coronary Artery Bypass Surgery

NCT01361594
View directory record Official record
Conditions
Diabetes
Interventions
Regular insulin (intensive treatment), Regular Insulin (conventional treatment)
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Not applicable Interventional

Insulin on Post Burn Hypermetabolism

NCT00137254
View directory record Official record
Conditions
Burns
Interventions
Insulin, Stable Isotopes, Indocyanine Green
Drug
Lead sponsor
United States Army Institute of Surgical Research
Federal
Eligibility
18 Years to 72 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 11, 2012 · Synced Sep 9, 2026, 4:46 AM EDT
Completed Phase 4 Interventional Results available

A Post-Marketing Study of the Immunogenicity of Somatropin (Ribosomal Deoxyribo Nucleic Acid [rDNA] Origin) Injection (Nutropin AQ®) in Children With Growth Hormone Deficiency

NCT02311894
View directory record Official record
Conditions
Growth Hormone Deficiency
Interventions
Somatropin
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
3 Years to 14 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
33
States / cities
Little Rock, Arkansas • Orange, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 9, 2026, 4:46 AM EDT